Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response
Sign Up to like & getrecommendations! Published in 2024 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2024-009901
Abstract: Background Bispecific T-cell engagers (BiTEs) are recombinant bispecific proteins designed to stimulate polyclonal T-cell immunity. In recent years, B7H3, a pan-cancer antigen, has been considered a promising target for future immunotherapy. However, the B7H3-targeting BiTE… read more here.
Keywords: b7h3 bite; b7h3; targeting bite; cell ... See more keywords